The Use of Recombinant Coagulation Factor VIIa (NovoSeven) in Severe Diverticular Bleeding

Guenin, Marc-Olivier; Peterli, Ralph; Kern, Beatrice; Ackermann, Christoph
January 2008
Open Surgery Journal;2008, Vol. 2, p1
Academic Journal
Case Study
We report a 68-year-old man with sigmoid colon carcinoma who previously underwent an anterior resection. Five years later, he developed a severe diverticular bleeding which required multiple blood transfusions. He underwent an emergent low anterior colectomy with a right colostomy to protect the anastomosis. Nine days after the operation, he had another severe bleeding. Due to his elderly age and two previous colectomies, recombinant coagulation factor VIIa (rFVIIa) was given to avoid re-operation. The bleeding stopped after two doses of rFVIIa, 80 μg/kg followed by 40 μg/kg one hour later. There was no bleeding recurrence.


Related Articles

  • Behandlung von polytraumatisierten Patienten. Grottke, O.; Spahn, D.R.; Rossaint, R. // Anaesthesist;Jun2011, Vol. 60 Issue 6, p546 

    Despite improved strategies in the treatment of polytraumatized patients the mortality rate of severely injured patients remains high. Thus, worldwide 5 million patients die due to trauma or trauma-related complications each year. As the majority of early trauma-related deaths are attributed to...

  • Recombinant Factor VIIa for Life-Threatening Hemorrhage in Trauma Patients: Review of the Literature. Pape, Hans-Christoph; Erhardtsen, Elisabeth; Meyer, Christian; Leppäniemi, Ari Kalevi // European Journal of Trauma;Oct2006, Vol. 32 Issue 5, p439 

    The control of hemorrhage and coagulopathy is a vital component of trauma care, and failure to achieve hemostasis can contribute to mortality. Recombinant factor VIIa (rFVIIa) is a well-established therapy for bleeding episodes and surgical prophylaxis in hemophilia patients with inhibitors....

  • Uses and abuses of fresh frozen plasma for the treatment of bleeding. Desborough, M. J.; Stanworth, S. J.; Curry, N. S. // Clinical Medicine;Apr2013, Vol. 13 Issue 2, p200 

    The article discusses the use of uses and abuses of fresh frozen plasma (FFP) for the treatment of bleeding. The article describes the mechanism by which FFP treats coagulopathy. The role of FFP in major bleeding associated with and without trauma, disseminated intravascular coagulation, and...

  • Prothrombin complex concentrate safely reverses warfarin-related bleeding. Huyen Tran; Sanjeev Chunilal // Evidence Based Medicine;Apr2014, Vol. 19 Issue 2, p75 

    The author reflects regarding the article "Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department," by M. Hickey and colleagues. Among the key topics that the authors have discussed include the link between Prothrombin complex...

  • Uses and abuses of fresh-frozen plasma for the prophylaxis of bleeding. Desborough, M. J.; Stanwort, S. J. // Clinical Medicine;Apr2013, Vol. 13 Issue 2, p197 

    The article presents questions and answers related to fresh-frozen plasma (FFP) including how FFP improves clinical outcomes, FFP's correction of abnormalities in coagulation tests, and the risks of FFP transfusion.

  • Improving the Management of Severe Hemophilia. Reding, Mark T. // Journal of Managed Care Medicine;2014, Vol. 17 Issue 1, p47 

    No abstract available.

  • Prothrombin Complex Preparations: A Cautionary Note. Ratnoff, Oscar D. // Annals of Internal Medicine;Dec74, Vol. 81 Issue 6, p852 

    Editorial. Focuses on the lethal outcome of the use of prothrombin complex preparations for treatment of bleeding. Overview of clotting factor transfusion; Consequences of prothrombin complex infusion; Recommendations.

  • Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders. Croom, Katherine F.; McCormack, Paul L. // BioDrugs;2008, Vol. 22 Issue 2, p121 

    Recombinant factor VIIa (NovoSeven; also known as recombinant activated factor VII or eptacog alfa) is structurally similar to human plasma-derived coagulation factor VIIa, but is manufactured using DNA biotechnology. Recombinant factor VIIa interacts with thrombin-activated platelets to...

  • Kogenate: home use Factor VIII and filtration.  // Australian Prescriber;Oct2012, Vol. 35 Issue 5, p163 

    The article informs about Kogenate, a recombinant human antihaemophilic Factor VIII used for the treatment and prophylaxis of bleeding in patients with hemophilia A and also mentions the importance of using the correct in-line filtration unit provided with the product.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics